BioMarin Gets Second PKU Approval, Anticipates Slow Ramp-Up For Palynziq

 
• By Joseph Haas

Analysts say black box warning of anaphylaxis risk and REMS were anticipated. Company plans a gradual rollout of Palynziq, focusing first on Phase III clinical trial sites and patients.

Array of blood samples for microscopy and biopsy tissue on blue gradient background

More from New Products

More from Scrip